Cargando…

The Complex Dynamic of Phase I Drug Metabolism in the Early Stages of Doxorubicin Resistance in Breast Cancer Cells

The altered activity of drug metabolism enzymes (DMEs) is a hallmark of chemotherapy resistance. Cytochrome P450s (CYPs), mainly CYP3A4, and several oxidoreductases are responsible for Phase I metabolism of doxorubicin (DOX), an anthracycline widely used in breast cancer (BC) treatment. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barata, Isabel S., Gomes, Bruno C., Rodrigues, António S., Rueff, José, Kranendonk, Michel, Esteves, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689592/ https://www.ncbi.nlm.nih.gov/pubmed/36360213 http://dx.doi.org/10.3390/genes13111977

Ejemplares similares

The Central Role of Cytochrome P450 in Xenobiotic Metabolism—A Brief Review on a Fascinating Enzyme Family
por: Esteves, Francisco, et al.
Publicado: (2021)

Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding
por: Esteves, Francisco, et al.
Publicado: (2020)

The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners
por: Esteves, Francisco, et al.
Publicado: (2020)

Corrigendum: The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners
por: Esteves, Francisco, et al.
Publicado: (2020)

Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
por: Campelo, Diana, et al.
Publicado: (2018)

Single Mutations in Cytochrome P450 Oxidoreductase Can Alter the Specificity of Human Cytochrome P450 1A2-Mediated Caffeine Metabolism
por: Esteves, Francisco, et al.
Publicado: (2023)

MicroRNAs and cancer drug resistance: over two thousand characters in search of a role
por: Gomes, Bruno Costa, et al.
Publicado: (2019)

Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
por: Bissett, D., et al.
Publicado: (1991)

ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance
por: Gomes, Bruno C., et al.
Publicado: (2020)

Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance
por: Armada, Ana, et al.
Publicado: (2019)

The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength
por: Campelo, Diana, et al.
Publicado: (2017)

Correction: The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength
por: Campelo, Diana, et al.
Publicado: (2018)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
por: Del Conte, G, et al.
Publicado: (2014)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
por: Hu, Wenxian, et al.
Publicado: (2021)

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
por: Matsumura, Y, et al.
Publicado: (2004)

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
por: González-Manzano, R., et al.
Publicado: (1995)

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)

Male and female breast cancer: the two faces of the same genetic susceptibility coin
por: Silva, Susana Nunes, et al.
Publicado: (2021)

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
por: Kristeleit, Rebecca, et al.
Publicado: (2021)

Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells
por: Lin, Shian-Ren, et al.
Publicado: (2020)

“Commandeuring” Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism
por: van Vugt-Lussenburg, Barbara M. A., et al.
Publicado: (2022)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma
por: Boyé, Pierre, et al.
Publicado: (2020)

A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis
por: Robella, Manuela, et al.
Publicado: (2021)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

P1605: OUTCOME OF SARS-COV-2 INFECTION IN HAEMATOLOGICAL CANCER PATIENTS (PTS) IN TWO DIFFERENT PANDEMIC PHASES AT A SINGLE CENTRE
por: Rodrigues, R., et al.
Publicado: (2022)

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy
por: Bagdasaryan, Alina A., et al.
Publicado: (2022)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Metastases
por: Robella, Manuela, et al.
Publicado: (2021)

Stage I endometrial adenocarcinoma with a vaginal nodule—the importance of differential diagnosis
por: Rodrigues, Isabel, et al.
Publicado: (2022)

Editorial: Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function
por: Pandey, Amit V., et al.
Publicado: (2017)

Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
por: Schirone, Leonardo, et al.
Publicado: (2022)

The Product of Matrix Metalloproteinase Cleavage of Doxorubicin Conjugate for Anticancer Drug Delivery: Calorimetric, Spectroscopic, and Molecular Dynamics Studies on Peptide–Doxorubicin Binding to DNA
por: Butowska, Kamila, et al.
Publicado: (2020)

Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo
por: Achkar, Iman W., et al.
Publicado: (2020)

Longitudinal Bioluminescence Imaging of the Dynamics of Doxorubicin Induced Apoptosis
por: Niu, Gang, et al.
Publicado: (2013)

PHB2 ameliorates Doxorubicin-induced cardiomyopathy through interaction with NDUFV2 and restoration of mitochondrial complex I function
por: Yang, Mingjie, et al.
Publicado: (2023)

Dynamic treatment regimes (DTRs) to study treatment sequencing in oncology: a scoping review protocol
por: Esteves, Susana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ai8dt08dgi8f5kmqg9hgc7inpj